Home
News
Create
Screeners
Insights
Beryl Drugs
21.
70
-0.05
(-0.23%)
Market Cap
₹10.97 Cr
PE Ratio
725.00
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.23%
1M
-5.24%
6M
-0.09%
1Y
-21.63%
5Y
+214.49%
View Company Insights
Latest news about Beryl Drugs
Beryl Drugs Limited Reports Q3 FY26 Net Loss of ₹16.77 Lacs Amid Manufacturing Challenges
Feb 09, 2026
Beryl Drugs Limited reported a net loss of ₹16.77 lacs in Q3 FY26 versus a profit of ₹5.22 lacs in Q3 FY25, with revenue declining 28.87% to ₹377.68 lacs. The pharmaceutical company faced operational disruptions due to manufacturing facility suspension from February to November 2025 following FDA directions. Operations resumed on November 28, 2025, after regulatory compliance, positioning the company for potential recovery in subsequent quarters.
Beryl Drugs Limited Files Q3FY26 Compliance Under Regulation 57(5) Stating Non-Applicability
Jan 06, 2026
Beryl Drugs Appoints Directors Under SEBI Regulation 30 Compliance Framework
Jan 03, 2026
Beryl Drugs Reports Q1 Net Profit of Rs 2.11 Lakhs Amid Partial Manufacturing Suspension
Aug 07, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation